Integrated DNA Technologies announces new licensing agreement with SeQure Dx to advance CRISPR-based therapeutics
July 16, 2024
Integrated DNA Technologies (IDT) inked a licensing agreement with SeQure Dx.
The licensing agreement enables IDT to support cell and gene therapy developers through all phases of their CRISPR-based therapeutic programs by providing comprehensive off-target analysis services, powered by SeQure Dx’s GUIDE-seq technology, alongside IDT’s rhAmpSeq CRISPR Analysis System.
The licensing agreement with SeQure Dx expands IDT’s comprehensive off-target analysis capabilities by providing the company access to SeQure Dx’s next generation sequencing-based gene editing off-target analysis technology, GUIDE-seq.
